FDA SITES (Pharmaceutical Executive)
The FDA home page is a deceptively simple door to a lot of information. Unless otherwise noted, nothing on the site is copyrighted -- neither text nor graphics. The public-domain material may be republished, reprinted, and used freely by anyone without obtaining permission from FDA.

Akorn, Inc. Announces FDA Approval For Unit Dose Preservative Free Tetanus Diphtheria Vaccine (Medical News Today)
Akorn, Inc. (NASDAQ:AKRX) announced FDA approval of a supplemental Biologics License Application (BLA) for a unit dose preservative free Tetanus Diphtheria vaccine. Akorn expects to launch this new vaccine in the first quarter of 2008. [click link for full article]

Natus reopens Seattle facility (bizjournals.com via Yahoo! Finance)
Natus Medical Inc. has resumed production and shipping operations at its Seattle facility, which was closed after an FDA inspection.